UK's MHRA Looks Beyond Brexit Transition Period
Working To Ensure Continuity Of Drug Regulation After 31 December
Executive Summary
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.